Home › NDC Lookup › Ingredients › Butenafine Hydrochloride › 51672-2100-02
Athletes Foot Butenafine Hydrochloride 10 mg/g Cream — NDC 51672-2100-02 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Athletes Foot Butenafine Hydrochloride 10 mg/g Cream — NDC 51672-2100-2 (Billing 51672-2100-02)

by Sun Pharmaceutical Industries, Inc. · 1 TUBE in 1 CARTON / 30 g in 1 TUBE

This is a package of Athletes Foot Butenafine Hydrochloride 10 mg/g Cream from Sun Pharmaceutical Industries, Inc., marketed since Nov 2017 and currently FDA-listed; retail pharmacies pay about $0.3070 per g (NADAC). It is the main listing for this product, which comes in 4 package sizes.

NDC 51672-2100-02
🏷️ FDA NDC (as labeled) 51672-2100-2 billing pads the package segment with a zero
This package
Contains30 g in 1 tube Cost per g$0.3070 NADAC Per package$9.21 / 30 g Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.5200/unit — full pricing hub ↓
Main listing for product 51672-2100 · Also comes in: 15 g 51672-2100-1 12 g 51672-2100-8 24 g 51672-2100-9
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 51672-2100-2 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
51672 labeler · 2100 product · 2 package
Package marketed since
Nov 17, 2017
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 5167221002 1
Medicaid fills, this package
1,795 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 51672-2100-2
Product NDC 51672-2100
11-digit billing NDC 51672210002
NCPDP billing unit GM — per gram (weight)
RxCUI 1298448
UNII R8XA2029ZI
Application # ANDA205181
SPL Set ID 4b400be5-acaa-4a5f-b8ef-c0df8ad6175f
Established class (EPC) Benzylamine Antifungal
Chemical class Benzylamines
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-11-17
Route TOPICAL
Dosage form CREAM
Substance BUTENAFINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90150026103720
GPI class Butenafine HCl
GCN Seq No 029333
GCN 37521
HICL code 012258
Ingredient (HICL) Butenafine Hcl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 84:04.08.12
AHFS class Benzylamines (Skin And Mucous Membrane)
FDB label name BUTENAFINE HCL 1% CREAM
FDB brand name Butenafine Hcl
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 029333
  • GCN: 37521
  • GPI-14 (Medi-Span): 90150026103720
  • HICL (First Databank): 012258
  • AHFS class code: 84:04.08.12
  • RxCUI (RxNorm): 1298448
Why two NDCs? The FDA registers this code as 51672-2100-2 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 51672-2100-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Benzylamine Antifungal class.

Pharmacologic class Benzylamine Antifungal
Drug family (ATC) Other antifungals for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name BUTENAFINE HCL 1% CREAM Ingredient Butenafine Hcl
📗 Our plain-language guide HelloPharmacist
  • It treats fungal skin infections. Depending on the product, that means athlete's foot between the toes, jock itch and ringworm. It also relieves itching, burning, cracking and scal...
  • Wash the area with soap and water and dry it completely. Then apply the cream as your product directs. Wash your hands afterward. Jock itch and ringworm are usually once a day for...
  • On products labeled for athlete's foot, the directions are twice a day for 1 week or once a day for 4 weeks, or as your doctor directs. Wear well-fitting, ventilated shoes and chan...
  • How long do I use it for athlete's foot?
📖 Read our full Butenafine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.307 $9.21 / 30 g
Medicaid paysCMS SDUD · 12 mo $0.5200 $15.60 / 30 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
Oct 2021 Feb 2026 May 2026 Sep 2026 $0.316 $0.304
▼ Down 3% over the last 11 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
51672-2100-01 51672-2100-1 1 TUBE in 1 CARTON / 15 g in 1 TUBE — — 2017-11-17 — Active
51672-2100-02 You're viewing this Main listing 1 TUBE in 1 CARTON / 30 g in 1 TUBE $0.3070 / g $9.21 2017-11-17 — Active
51672-2100-08 51672-2100-8 1 TUBE in 1 CARTON / 12 g in 1 TUBE $0.5301 / g $6.36 2017-11-17 — Active
51672-2100-09 51672-2100-9 1 TUBE in 1 CARTON / 24 g in 1 TUBE — — 2017-11-17 — Active

This pack has the lowest per-g cost of the 2 priced pack sizes ($0.3070 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 90% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 30 g in 1 tube.
What NDC number is used to bill for this package of Athletes Foot Butenafine Hydrochloride 10 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Athletes Foot 10 mg/gthis 51672-2100-02 Sun 1 tube $0.307 — Availability likely —
Athletes Foot 10 mg/g 70677-1269-01 STRATEGIC 1 tube $0.307 — Availability likely —
Athletes Foot 10 mg/g 00363-2100-02 Walgreen 1 tube — — FDA listed —
Jock Itch 10 mg/g 00363-2101-08 Walgreen 1 tube — — FDA listed —
Lotrimin Ultra 1 g/100g 11523-0082-01 Bayer 1 tube — — FDA listed —
Lotrimin Ultra Ringworm 1 g/100g 11523-0158-02 Bayer 1 tube — — FDA listed —
Lotrimin Ultra Athletes Foot 1 g/100g 11523-4338-01 Bayer 1 tube — — FDA listed —
Lotrimin Ultra Jock Itch 1 g/100g 11523-4339-01 Bayer 1 tube — — FDA listed —
Athletes Foot 10 mg/g 11673-0016-02 Target 1 tube — — FDA listed —
Jock Itch Cream 10 mg/g 11673-0436-01 TARGET 1 tube — — FDA listed —
Athletes Foot 10 mg/g 11822-2100-02 Rite 1 tube — — FDA listed —
Butenafine Hydrochloride 10 mg/g 21130-0965-01 Albertsons 1 tube — — FDA listed —
Butenafine Hydrochloride Athletes Foot 10 mg/g 30142-0210-02 Kroger 1 tube — — FDA listed —
Athletes Foot 10 mg/g 36800-0049-01 TOPCO 1 tube — — FDA listed —
Athletes Foot Ultra 10 mg/g 37808-0013-02 H 1 tube — — FDA listed —
Butenafine Hydrochloride Jock Itch 10 mg/g 49035-0178-08 Wal-Mart 1 tube — — FDA listed —
Athletes Foot Ultra 10 mg/g 49035-0225-08 Wal-Mart 1 tube — — FDA listed —
Jock Itch 10 mg/g 51672-2101-01 Sun 1 tube — — FDA listed —
Athletes Foot 10 mg/g 69842-0986-02 CVS 1 tube — — FDA listed —
Butenafine Hydrochloride 1% 10 mg/g 69842-0989-08 CVS 1 tube — — FDA listed —
Butenafine Hydrochloride 10 mg/g 73581-0210-02 YYBA 1 tube — — FDA listed —
Butenafine Hydrochloride 10 mg/g 79481-0086-01 MEIJER 1 tube — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
On the market since
Nov 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Butenafine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII 495CTZ441V
    Ceteth-23 is a synthetic emulsifier made by combining cetyl alcohol with ethylene oxide. It helps mix oil and water in liquid formulations and improves how the medicine spreads on skin or is absorbed.
  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
  • UNII 581437HWX2
    A synthetic oily liquid made from propylene glycol and fatty acids. It works as an emollient and solubilizer in medicines, helping dissolve active ingredients and improve how the product spreads or absorbs.
  • UNII OJ245FE5EU
    Sodium benzoate is a salt derived from benzoic acid, a preservative. It's added to medicines to prevent growth of bacteria, fungi, and other microorganisms that could spoil the product.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
  • UNII 9O3K93S3TK
    Trolamine is an alkaline compound used as a pH buffer and emulsifier in medicines. It helps neutralize acids, stabilize formulations, and enable mixing of oil and water-based ingredients.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

10 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesbenzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23) cetyl ether, propylene glycol dicaprylate, purified water, sodium benzoate, stearic acid, trolamine, white petrolatum

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSun Pharmaceutical Industries, Inc.
Application holderSUN PHARMA CANADA INC
FDA applicationANDA205181 (ANDA)
Labeler code51672
First marketedNov 2017
Product typeHuman Otc Drug
Portfolio890 products on file

More NDCs from Sun Pharmaceutical Industries, Inc. labeler code 51672

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 34 words ▾

Uses cures most athlete's foot between the toes. Effectiveness on the bottom or sides of foot is unknown. cures most jock itch and ringworm relieves itching, burning, cracking, and scaling which accompany these conditions

⏱️ Dosage and Administration 124 words ▾

Directions adults and children 12 years and older: use the tip of the cap to break the seal and open the tube wash the affected skin with soap and water and dry completely before applying for athlete's foot between the toes: apply to affected skin between and around the toes twice a day for 1 week (morning and night), or once a day for 4 weeks, or as directed by a doctor. Wear well-fitting, ventilated shoes. Change shoes and socks at least once daily.

Apply between and around the toes for jock itch and ringworm: apply once a day to affected skin for 2 weeks or as directed by a doctor. wash hands after each use children under 12 years: ask a doctor Figure

⚠️ Warnings 76 words ▾

Warnings For external use only Do not use on nails or scalp in or near the mouth or the eyes for vaginal yeast infections When using this product do not get into the eyes. If eye contact occurs, rinse thoroughly with water. Stop use and ask a doctor if too much irritation occurs or irritation gets worse Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📦 Storage and Handling 24 words ▾

Other information do not use if seal on tube is broken or not visible store between 20° to 25° C (68° to 77° F)

🧪 Active Ingredient 5 words ▾

Active ingredient Butenafine hydrochloride 1%

🧪 Inactive Ingredients 26 words ▾

Inactive ingredients benzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23) cetyl ether, propylene glycol dicaprylate, purified water, sodium benzoate, stearic acid, trolamine, white petrolatum

🎯 Purpose 2 words ▾

Purpose Antifungal

📄 Do Not Use 19 words ▾

Do not use on nails or scalp in or near the mouth or the eyes for vaginal yeast infections

📄 When Using This Product 18 words ▾

When using this product do not get into the eyes. If eye contact occurs, rinse thoroughly with water.

📄 Stop Use and Ask a Doctor If 15 words ▾

Stop use and ask a doctor if too much irritation occurs or irritation gets worse

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Questions or Comments 3 words ▾

Questions? Call 1-866-923-4914

📄 Package Label / Principal Display Panel 37 words ▾

PRINCIPAL DISPLAY PANEL - 15 g Tube Carton Clinically Proven to Cure Most Athlete's Foot between the Toes Butenafine Hydrochloride Cream 1% Antifungal NET WT 15 g (0.53 oz) Principal Display Panel - 15 g Tube Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.8K
Units reimbursed last 4 qtrs
65.2K
Gross reimbursed last 4 qtrs
$33.9K
Avg / prescription
$18.90
Avg / unit
$0.5200
Latest quarter Q1 2026
389Rx
Medicaid pays / g
$0.5200
gross reimbursed
vs
NADAC / g
$0.3070
acquisition cost
=
Spread
+$0.2130
+69% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
70% FFS 30% MCO
Fee-for-service · 1,252 Rx Managed care · 543 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 3,554 units · 18.2 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 5,160 units · 43.8 per 100k residents OH Pennsylvania: 13,965 units · 108 per 100k residents PA New Jersey: 930 units · 10.0 per 100k residents NJ Massachusetts: no data reported MA California: 39,593 units · 102 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 1,710 units · 27.6 per 100k residents MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 330 units · 4.4 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
4.4108
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Pennsylvania 108 /100k
2 California 102 /100k
3 Ohio 43.8 /100k
4 Missouri 27.6 /100k
5 New York 18.2 /100k
6 New Jersey 10.0 /100k
7 Arizona 4.4 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page51672-2100-02 1,795 Rx · $33,926
1 tube51672-2100-08 189 Rx · $3,984
1 tube51672-2100-01 No Medicaid data
1 tube51672-2100-09 No Medicaid data
Drug total (last 4 qtrs): 1,984 Rx · 69,454 units · $37,911 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Athletes Foot (this brand).

Top reported reactions

Nausea910
Pain881
Headache814
Macular Degeneration812
Dyspnoea802
Fatigue731
Diarrhoea677

Age at onset

Neonate47
Infant20
Child41
Adolescent25
Adult1,316
Elderly1,057

Reporter sex

14,249 reports
Male · 35%
Female · 65%
Unknown · 0%

Serious outcomes

Hospitalization4,634
Death1,070
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,101 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 51672-2089-02 · Sun 51672-2101-01 · Sun →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.